Association of humoral antitumor response with clinical benefit in catumaxomab-treated malignant ascites patients: Results from a phase IIIb study.

被引：0
|
作者：
Ruf, Peter
Suckstorff, Ivonne
Jaeger, Michael
Ernst, Christine
Seimetz, Diane
Lindhofer, Horst
机构：
[1] TRION Res GmbH, Martinsried, Germany
[2] Fresenius Biotech GmbH, Munich, Germany
[3] TRION Res GmbH, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2584
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab: Results From a Multicenter Phase II/III Study Comparing Paracentesis Plus Catumaxomab With Paracentesis Alone
    Gonschior, A.
    Gilet, H.
    Heisss, M. M.
    Hennig, M.
    Moehler, M.
    Schmalfeldt, B.
    Schulze, E.
    Wimberger, P.
    Parsons, S. L.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S223 - S223
  • [12] Quality of life in patients with malignant ascites and after treatment with catumaxomab: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone
    Schmalfeldt, B.
    Seck, K.
    Gonschior, A. K.
    Gilet, H.
    Heiss, M.
    Hennig, M.
    Moehler, M.
    Schulze, E.
    Wimberger, P.
    Parsons, S. L.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2012, 72 (04)
  • [13] The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study
    Heiss, Markus M.
    Stroehlein, Michael A.
    Bokemeyer, Carsten
    Arnold, Dirk
    Parsons, Simon L.
    Seimetz, Diane
    Lindhofer, Horst
    Schulze, Elisabeth
    Hennig, Michael
    CLINICAL CANCER RESEARCH, 2014, 20 (12) : 3348 - 3357
  • [14] Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study
    Parsons, S. L.
    Kutarska, E.
    Koralewski, P.
    Gore, M.
    Wimberger, P.
    Burges, A.
    Stroehlein, M. A.
    Lahr, A.
    Jaeger, M.
    Heiss, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [15] The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Follow-up results from a phase II/III study.
    Heiss, M. M.
    Stroehlein, M. A.
    Bokemeyer, C.
    Arnold, D.
    Parsons, S. L.
    Ott, M. G.
    Schulze, E.
    Lindhofer, H.
    Seimetz, D.
    Hennig, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [16] Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study
    Jaeger, M.
    Schoberth, A.
    Theissen, B.
    Hess, J.
    Friccius-Quecke, H.
    Lindhofer, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [17] Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone
    Wimberger, P.
    Gilet, H.
    Gonschior, A-K.
    Heiss, M. M.
    Moehler, M.
    Oskay-Oezcelik, G.
    Al-Batran, S-E.
    Schmalfeldt, B.
    Schmittel, A.
    Schulze, E.
    Parsons, S. L.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 1979 - 1985
  • [18] Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)
    Jaeger, Michael
    Schoberth, Alexandra
    Ruf, Peter
    Hess, Juergen
    Hennig, Michael
    Schmalfeldt, Barbara
    Wimberger, Pauline
    Stroehlein, Michael
    Theissen, Bettina
    Heiss, Markus M.
    Lindhofer, Horst
    CANCER RESEARCH, 2012, 72 (01) : 24 - 32
  • [19] Treatment with the trifunctional antibody catumaxomab followed by systemic chemotherapy: Results of a subgroup analysis from a phase III study in patients with relapsed ovarian cancer and malignant ascites
    Chekerov, R.
    Wimberger, P.
    Vergote, I.
    Schneeweiss, A.
    Scambia, G.
    Colombo, N.
    Guastalla, J. P.
    Lordick, F.
    Schulze, E.
    Sehouli, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S742 - S742
  • [20] MAINTENANCE OF QUALITY OF LIFE IN PATIENTS WITH MALIGNANT ASCITES DURING TREATMENT WITH THE TRIFUNCTIONAL ANTIBODY CATUMAXOMAB: RESULTS FROM THE PHASE III B CASIMAS TRIAL
    Lordick, F.
    Sehouli, J.
    Vergote, I. B.
    Rosenberg, P.
    Schneeweiss, A.
    Block, A.
    Salat, C.
    Scambia, G.
    Berton-Rigaud, D.
    Wimberger, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 514 - 514
12345